Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?

Guillaume Richard-Carpentier; Guy Sauvageau

doi:10.1016/j.stem.2017.02.010

Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?

Cell Stem Cell. 2017 Mar 2;20(3):300-301. doi: 10.1016/j.stem.2017.02.010.

Authors

Guillaume Richard-Carpentier¹, Guy Sauvageau²

Affiliations

¹ The Leucegene Project at the Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3C 3J7, Canada; Banque de Cellules Leucémiques du Quebec, Maisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada.
² The Leucegene Project at the Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3C 3J7, Canada; Division of Hematology, Maisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada; Banque de Cellules Leucémiques du Quebec, Maisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada; Department of Medicine, Faculty of Medicine, Université de Montréal, QC H3T 1J4, Canada. Electronic address: [email protected].

PMID: 28257710
DOI: 10.1016/j.stem.2017.02.010

Abstract

Prognostic markers that capture leukemia stem cell (LSC) activity can be useful for the risk stratification of acute myeloid leukemia (AML) patients. In a recent issue of Nature, Ng et al. (2016) develop a prognostic score based on a 17-gene expression signature of LSCs to predict outcome in AML patients.

Publication types

Comment

MeSH terms

Acute Disease
Humans
Leukemia, Myeloid, Acute / genetics*
Neoplastic Stem Cells*
Transcriptome